<DOC>
	<DOCNO>NCT00202774</DOCNO>
	<brief_summary>The purpose study determine time disease progression combination therapy capecitabine oxaliplatin ( XELOX ) vs. oxaliplatin 5-fluorouracil continous infusion ( 5-FU CI ) first line treatment advance metastatic colorectal cancer</brief_summary>
	<brief_title>Safety Efficacy Study XELOX vs. Oxaliplatin+5-FU CI First Line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The purpose study determine time disease progression combination therapy capecitabine oxaliplatin ( XELOX ) vs. oxaliplatin 5-fluorouracil continous infusion ( 5-FU CI ) first line treatment advance metastatic colorectal cancer</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Written inform consent . Men woman &gt; = 18 year Karnofsky functional status &gt; or=70 % time enrollment study Histologically confirm diagnosis CRC Patients must receive chemotherapy ( exception : adjuvant treatment &gt; 12 month follow conclusion treatment ) Presence least one lesion detectable twodimensional measurement.. Life expectancy great 3 month . Pregnant nursing woman Prior administration systemic immunotherapy , chemotherapy ( exception : 5FU adjuvant treatment &gt; 12 month follow conclusion treatment ) Evidence allergic reaction treatment component Clinically relevant myocardial disease history myocardial infarction past 12 month Documented suspected cerebral and/or leptomeningeal metastasis . Prior malignant tumour past 5 year , except history basal cell skin carcinoma preinvasive cervical carcinoma . Neutrophil count &lt; 1.5 x 109/l , platelet &lt; 100 X 109/l serum creatinine &gt; 1.5 x ULN . Total bilirubin count &gt; 2 x ULN Alkaline Phosphatase &gt; &gt; 2.5 x ULN ( &gt; 5 x ULN hepatic metastasis ) Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &gt; 2.5 x ULN ( &gt; 5 x ULN hepatic metastasis , &gt; 10 x ULN bone metastasis ) Creatinine clearance &lt; 30 ml/min Surgery within 4 week prior enrollment study . Any investigational drug 4 week prior enrolment . Uncontrolled active infection Any medical psychological disorder , opinion investigator , allow patient conclude study sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>colorectal cancer , capecitabine , oxaliplatin , 5-fluorouracil</keyword>
</DOC>